Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-10-2000 | Meeting abstract

An evaluation of the relationship between compressed breast thickness and glandular dose, within the breast screening service

Author: S Simpson

Published in: Breast Cancer Research | Special Issue 2/2000

Login to get access

Excerpt

This project aims to investigate the relationship between compressed breast thickness (CBT) in mm and mean glandular dose (MGD) in mGy for two differing mammography units. The units are a 28 Kvp fixed molybdenum filter and target mammomat (Siemens 300) (Young et al 1996) and an Automatic Quality Beam System unit, which alters Kvp, filter and target material (Siemens 3000) (Young et al 1996), both units being commonly used in the NHSBSP. The outcome revealed that using a fixed 28 Kvp molybdenum filter and target, the CBT and MGD relationship exists exponentially. Breasts with a CBT of greater than 60 mm were at risk of receiving a MGD greater than recommended by NHSBSP Publication 37 1998, of 2 mGy. The Automatic Quality Beam System demonstrated overall a more erratic relationship between CBT and MGD, mainly due to target and filter material changing. However, it allowed the MGD at greater values of CBT to be reduced, with 2 mGy not exceeded up to 70 mm CBT. The use of Automatic Quality Beam System mammomats is highly recommended within the NHSBSP to maximise image quality while maintaining low glandular dose. …
Metadata
Title
An evaluation of the relationship between compressed breast thickness and glandular dose, within the breast screening service
Author
S Simpson
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr254

Other articles of this Special Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine